Table 1.
Demographic and clinical characteristics of patients and healthy volunteers at the time of study inclusion
| CRPC patients | n=41 |
|---|---|
| Age (yr) | |
| Median | 70 |
| Range | 40–82 |
| Serum PSA (ng/mL) | |
| Median | 90 |
| Range | 2–2532 |
| LDH (U/L) | |
| Median | 170 |
| Range | 112–678 |
| Albumin (g/L) | |
| Median | 35 |
| Range | 24–42 |
| Haemoglobin (g/dL) | |
| Median | 12.2 |
| Range | 8.3–15.5 |
| Sites of metastases | |
| Bone | 39 (95%) |
| Nodal | 28 (68%) |
| Visceral | 13 (32%) |
| ECOG performance score | |
| 0 | 6 (15%) |
| 1 | 33 (80%) |
| 2 | 2 (5%) |
| Previous CRPC therapies (n) | |
| Median | 3 |
| Range | 1–5 |
| Previous therapies | |
| Bicalutamide | 41 (100%) |
| Docetaxel | 26 (63%) |
| Cabazitaxel | 4 (10%) |
| Abiraterone (AA) | 14 (34%) |
| Enzalutamide (E) | 3 (7%) |
| Investigational agents | 13 (32%) |
|
| |
| Healthy Volunteers | n=20 |
|
| |
| Age (yr) | |
| Median | 33.5 |
| Range | 21–53 |
| Sex | |
| Male | 10 |
| Female | 10 |
CRPC = castration resistant prostate cancer